[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 1990

Comparison of Acellular and Whole-Cell Pertussis-Component DTP Vaccines: A Multicenter Double-blind Study in 4- to 6-Year-Old Children

Author Affiliations

From the Departments of Pediatrics (Drs Morgan, Blumberg, and Cherry) and Biomathematics (Dr Christenson), UCLA School of Medicine; Pittsburgh (Pa) Pediatric Research (Drs Reisinger and Blatter); Rainbow Babies and Children's Hospital, Cleveland, Ohio (Dr Blumer); and Lederle Biologicals, Pearl River, NY (Drs Dekker and Stout).

Am J Dis Child. 1990;144(1):41-45. doi:10.1001/archpedi.1990.02150250047029

• An acellular pertussis-component combined diphtheria and tetanus toxoids, and pertussis (APDT) vaccine adsorbed was compared with a licensed whole-cell pertussis-component combined diphtheria and tetanus toxoids, and pertussis (DTP) vaccine adsorbed for reactogenicity and immunogenicity when given as the fifth DTP immunization to eighty-two 4- to 6-year-old children. The reaction rates with both vaccines were low; APDT vaccine recipients had significantly less pain and warmth at the injection site than did DTP vaccine recipients. Antibody responses to pertussis antigens (lymphocytosis-promoting factor, filamentous hemagglutinin, and agglutinogens) and to diphtheria and tetanus toxoids were all brisk. The APDT vaccine recipients had a more marked response in antibodies to filamentous hemagglutinin and a less marked response in agglutinins than whole-cell vaccine recipients. On the day after immunization, both APDT and DTP vaccine recipients had an increase in mean leukocyte and neutrophil counts. This APDT vaccine is immunogenic and less reactogenic than a DTP vaccine with a whole-cell pertussis component when administered as a booster to 4- to 6-year-old children.

(AJDC. 1990;144:41-45)